Immune detection of acetylcholinesterase in subcellular compartments of Trypanosoma evansi

Mijares, Alfrédo; Concepción, Juan Luís; Vielma, José Ramón; Portillo, R.

doi:10.1007/s00436-010-2032-6

Cited by 6 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tachyzoites of T. gondii showed the presence of AChE enzyme, similar to what was observed in other parasites such as Schistosoma mansoni, trypanosomes, helminths of the family Trichostrongylidae and ticks (Mallet et al 1997;Arnon et al 1999;Joshi and Singh 2000;Bollo et al 2001;Mijares et al 2011;Ribeiro et al 2012). Research shows that this enzyme plays different roles in the parasite, increasing its survival.…”

Section: Resultssupporting

confidence: 50%

“…In trypanosomes, nicotinic receptors and the enzyme AChE participate in the regulation of calcium in the parasite (Bollo et al 2001;Mijares et al 2011). Although the enzyme AChE can be described in the genome of the T. gondii ME-49 strain (Lorenzi et al 2008), the AChE activity in parasite has not been studied and not explored in chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Acetylcholinesterase activity in Toxoplasma gondii tachyzoites (RH strain)

et al. 2014

View full text Add to dashboard Cite

This study aimed to investigate acetylcholinesterase (AChE) presence and its enzymatic activity in Toxoplasma gondii (RH strain) tachyzoites and to test a well-known inhibitor of this enzyme. Tachyzoites were obtained from cell culture (sample 1) and peritoneal fluid of experimentally infected mice (sample 2). The protein concentration was determined for each pellet of tachyzoite. In this study, our hypothesis is that T. gondii has the enzyme AChE just like other parasites, and this knowledge might be helpful to develop new chemotherapy strategies to fight toxoplasmosis. The AChE activity was detected in the parasite using 0.025, 0.05, 0.1, 0.2, 0.4, 0.7, and 1.0 mg mL −1 concentrations of protein from tachyzoites. AChE activity has increased progressively according to protein increase, up to a certain point, when it had reduced activity when higher concentrations of protein were tested. The AChE activity of T. gondii was also inhibited with the use of trichlorfon, similar to what occurs with other parasites. Based on these results, we conclude that the enzyme AChE is present in T. gondii tachyzoites. Trichlorfon is able to inhibit the enzyme detected in this study, which might become an option for chemotherapy.

show abstract

Section: Resultssupporting

confidence: 50%

Section: Introductionmentioning

confidence: 99%

Acetylcholinesterase activity in Toxoplasma gondii tachyzoites (RH strain)

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Unlike for MAO-A, an AChE has been reported to be present in the glycosome of T. evansi , which might act by regulating the flow of Ca +2 between the organelle and the cytosol [30]. However, as with MAO-A, the present results (Table 5) showed that compounds OXO 1 and OXO 13 exerted only moderate inhibitory activity against AChE in comparison with the rasagiline used as a control, and more importantly, both compounds exerted similar inhibitory activity.…”

Section: Discussionmentioning

confidence: 99%

Synthetic Oxoisoaporphine Alkaloids: In Vitro, In Vivo and In Silico Assessment of Antileishmanial Activities

et al. 2013

View full text Add to dashboard Cite

Leishmaniasis is a growing health problem worldwide. As there are certain drawbacks with the drugs currently used to treat human leishmaniasis and resistance to these drugs is emerging, there is a need to develop novel antileishmanial compounds, among which isoquinoline alkaloids are promising candidates. In this study, 18 novel oxoisoaporphine derivatives were synthesized and their possible antileishmanial activity was evaluated. The in vitro activity of these derivatives against Leishmania amazonensis axenic amastigotes was first evaluated, and the selected compounds were then tested in an inhibition assay with promastigotes of L. infantum, L. braziliensis, L. amazonensis and L. guyanensis, and with intracellular amastigotes of L. infantum and L. amazonensis. Finally, the most active compounds, OXO 1 (2,3-dihydro-7H-dibenzo[de,h]quinolin-7-one) and OXO 13 (2,3,8,9,10,11-hexahydro-7H-dibenzo[de,h]quinolin-7-one), were tested in BALB/c mice infected with L. infantum. Treatment of mice at a dose of 10 mg/kg with OXO 1 yielded significant reductions (p<0.05) in parasite burden in liver and spleen (99% and 78%, respectively) whereas with OXO 13 were not significant. Although previous reports suggest that this family of molecules displays inhibitory activity against monoamine oxidase A and acetylcholinesterase, these enzymes were not confirmed as targets for antileishmanial activity on the basis of the present results. However, after development of a new bioinformatics model to analyze the Leishmania proteome, we were able to identify other putative targets for these molecules. The most promising candidates were four proteins: two putative pteridine reductase 2 (1MXF and 1MXH), one N-myristoyltransferase (2WUU) and one type I topoisomerase (2B9S).

show abstract

“…Immunization with rSmStoLP-2 engendered 32% reduction in adult worm burden and a Th1 predominant immune response [29]. Dif5 gene, a possible homologue of human CD59/LY6, predicted to be GPI-anchored on the S. mansoni tegument surface conferred 22% reduction in adult worm burden in mice immunized with the Dif5 gene as DNA vaccine [48]. …”

Section: Tegument Proteins As Vaccine Candidatesmentioning

confidence: 99%

Computational Vaccinology: An Important Strategy to Discover New PotentialS. mansoniVaccine Candidates

Pinheiro

Martins

Assis

et al. 2011

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

The flatworm Schistosoma mansoni is a blood fluke parasite that causes schistosomiasis, a debilitating disease that occurs throughout the developing world. Current schistosomiasis control strategies are mainly based on chemotherapy, but many researchers believe that the best long-term strategy to control schistosomiasis is through immunization with an antischistosomiasis vaccine combined with drug treatment. Several papers on Schistosoma mansoni vaccine and drug development have been published in the past few years, representing an important field of study. The advent of technologies that allow large-scale studies of genes and proteins had a remarkable impact on the screening of new and potential vaccine candidates in schistosomiasis. In this postgenomic scenario, bioinformatic technologies have emerged as important tools to mine transcriptomic, genomic, and proteomic databases. These new perspectives are leading to a new round of rational vaccine development. Herein, we discuss different strategies to identify potential S. mansoni vaccine candidates using computational vaccinology.

show abstract

Immune detection of acetylcholinesterase in subcellular compartments of Trypanosoma evansi

Cited by 6 publications

References 24 publications

Acetylcholinesterase activity in Toxoplasma gondii tachyzoites (RH strain)

Acetylcholinesterase activity in Toxoplasma gondii tachyzoites (RH strain)

Synthetic Oxoisoaporphine Alkaloids: In Vitro, In Vivo and In Silico Assessment of Antileishmanial Activities

Computational Vaccinology: An Important Strategy to Discover New PotentialS. mansoniVaccine Candidates

Contact Info

Product

Resources

About